HONG KONG – South Korea's Celltrion Inc. will be the first foreign company in China to initiate clinical trials of an antibody biosimilar. The company recently received the go-ahead from the CFDA for a trial testing Remsima (infliximab), based on an application submitted two years ago under the agency's IND program.
HONG KONG – South Korea’s Celltrion Inc. will be the first foreign company in China to initiate clinical trials of an antibody biosimilar. The company recently received the go-ahead from the CFDA for a trial testing Remsima (infliximab), based on an application submitted two years ago under the agency’s IND program.
HONG KONG – A deal inked between Carlsbad, Calif.-based Ionis Pharmaceuticals Inc. and Kunshan, China-based Suzhou Ribo Life Science Co. Ltd. will ease the U.S. company's entry into the Chinese innovative drug market, while Ribo picks up a license for two antisense drugs – and an option for a third – aimed at treating metabolic diseases and cancer.
